

If you purchased brand or generic Truvada or Atripla directly from the manufacturer, you may receive a payment from a class action settlement. Under the settlement, Gilead agreed to pay \$246,750,000 into a Settlement Fund.

A federal court authorized this notice. This is not a solicitation from a lawyer.

A proposed Settlement has been reached in a class action lawsuit (*KPH Healthcare Services, Inc. v. Gilead Sciences, Inc.*, No. 3:20-cv-06961-EMC (N.D. Cal.), coordinated with *In re HIV Antitrust Litigation* (formerly called *Staley v. Gilead Sciences, Inc.*), No. 3:19-cv-02573-EMC (N.D. Cal.)). The lawsuit alleges that Defendants Gilead and BMS engaged in a variety of allegedly anticompetitive conduct that caused direct purchasers to pay too much for HIV drugs. This Settlement resolves the claims against Gilead. A previous settlement resolved the claims against BMS. Gilead and BMS deny any wrongdoing. The Court has not decided who is right.

WHO IS INCLUDED IN THE SETTLEMENT?

Generally, the Settlement includes entities that purchased Truvada and Atripla, or their generic equivalents, directly from a brand or generic manufacturer from February 1, 2018 until September 27, 2022.

WHAT DOES THE SETTLEMENT PROVIDE?

Gilead agreed to pay \$246,750,000 into a Settlement Fund.

If the Court approves the Settlement, Class Counsel will seek reimbursement for litigation costs and expenses up to \$4 million, attorneys' fees of up to 33 ⅓% of the Gilead Settlement Fund (up to \$82,250,000), and payment of a class representative service award in the amount of \$40,000. These amounts, if approved, will be paid from the Settlement Fund.

The full text of the Settlement is available for inspection at www.HIVDirectPurchaserClass.com.

HOW CAN YOU GET A PAYMENT?

If the Court approves the Settlement, to get paid, you must submit a Claim Form by January 1, 2024, either online (at www.HIVDirectPurchaserClass.com) or by U.S. Mail. You may have received a personalized Claim Form with pre-populated information based on available transactional data. If not, a Claim Form is available at www.HIVDirectPurchaserClass.com. See the Claim Form for instructions on how to make any corrections or supplements and submit the form. If the Court approves the Settlement, claims will be paid after the conclusion of any appeals.

WHAT ARE YOUR OTHER OPTIONS?

You may write to the Court about why you do not like the Settlement. The objection must be filed by December 28, 2023. Additionally, you may ask to go to the Final Approval Hearing and speak in Court about the fairness of the Settlement. If you object to the Settlement, you are still a member of the Settlement Class(es) and you must file a claim to receive a payment. Descriptions about the effects of objecting, and instructions on how to object, are in the detailed notice available at www.HIVDirectPurchaserClass.com.

The Court scheduled a hearing for January 18, 2024 at 1:30 p.m. Pacific Time to consider any objections and whether the Settlement and allocations are fair, reasonable, and adequate. You do not need to attend, but you or your attorney can do so at your own expense. See the detailed notice available at www.HIVDirectPurchaserClass.com for the hearing location, where to find out if the date or time changes, and what you must do if you or your attorney wishes to speak at the hearing.

FOR MORE INFORMATION VISIT www.HIVDirectPurchaserClass.com OR CALL (501) 821-5575